Abstract

A wearable respiratory rate sensing device The device comprising: a processor, connectable to an audio sensor configured to: receive captured in-ear audio data from the audio sensor; detect, from the captured in-ear audio data, a scenario of the wearer; select, based on the detected scenario, an in- ear audio data processing pipeline from a plurality of in-ear audio data processing pipelines; and derive, by applying the selected in-ear audio data processing pipeline to the captured in-ear audio data, a respiratory rate of the wearer.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 7/00 - Instruments for auscultation
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention provides a ligand comprising a first binding moiety which binds to tau assemblies, and a second binding moiety which is bound by TRIM21 for use in the treatment of neurodegenerative disease in the cytoplasm of a neuronal cell, wherein the ligand is administered extracellularly.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a conjugate, in particular to a conjugate comprising an antigen- binding moiety and the C-terminal domain of proprotein convertase subtilisin/kexin type 9 (PCSK9) or a homolog thereof, wherein the antigen-binding moiety is operable to bind to a receptor on the surface of a cell, and wherein the receptor is constitutively internalised and recycled. The conjugates may be used in methods for degrading a cell surface receptor and/or inhibiting the growth of a cell.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

The present invention relates to novel combination therapies for the treatment of ALL. The combination therapies comprises the administration of a BCL2 inhibitor in combination with a CREBBP and/or EP300 inhibitor.

IPC Classes  ?

• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/11 - Aldehydes
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Described herein are zeolite bodies, in particular those having improved physical and chemical properties, methods of manufacturing the zeolite bodies, and uses of the zeolite bodies, in particular in catalysis and gas separation.

IPC Classes  ?

• C01B 39/40 - Type ZSM-5 using at least one organic template directing agent

Abstract

The present invention relates to antibody conjugates, and methods of manufacturing the same. In particular, the present invention relates to a conjugate comprising an antibody, a linker and at least one active agent, wherein: the linker connects the at least one active agent(s) to the antibody; ii) the linker is attached to the antibody through 5 to 8 independent covalent bonds; and iii) each covalent bond between the linker and the antibody is formed from the reaction between a sulfur atom on the antibody and a functional group on the linker.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

The present invention relates to plant-operable promoter sequences and regulatory sequences derived therefrom. The present invention also relates to uses of such promoters to confer improved gene expression, especially in bundle sheath cells. The invention further relates to plants comprising said promoter sequences operably linked to downstream plant genes, to methods for obtaining said plants and to plants obtainable by such methods. The present invention also relates to methods and genetic constructs for specifically expressing genes in bundle sheath cells in plants.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

A method of sensing, comprising the steps of exposing a sensing device to a gas phase analyte and subjecting the sensing device to AC excitation and measuring a DC conductance of the sensing device. The sensing device comprises discrete carbon-based electrically conducting regions on a surface of an electrically insulating carbon-based material substrate. Electrical conduction through the sensing device is by percolation between the electrically conducting regions. Interaction between the gas phase analyte and the discrete carbon-based electrically conducting regions affects the DC conductance to enable sensing of the analyte. Sensing devices configured to be used in such methods of sensing, and methods of manufacturing such sensing devices.

IPC Classes  ?

• G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

A method of producing an electronic device, the method comprising: modifying a charge carrier density of an electrically conductive material, the electrically conductive material comprising an ionic material, wherein modifying the charge carrier density of the electrically conductive material comprises modifying the charge carrier density while the electrically conductive material is in a state such that ionic motion of the ionic material is frozen. An electronic device is also described.

IPC Classes  ?

• H10K 71/30 - Doping active layers, e.g. electron transporting layers
• H10K 85/10 - Organic polymers or oligomers
• H10N 10/856 - Thermoelectric active materials comprising organic compositions

Abstract

This invention relates to the treatment of inflammation, or diseases characterised by excessive or aberrant activation of the NLR family Pyrin Domain Containing 3 (NLRP3) inflammasome, such as cardiac dysfunction, by reducing the expression and/or activity of Polo-like kinase 1 (PLK1). In some embodiments, treatment may comprise administering a PLK1 inhibitor to an individual in need thereof. Methods of screening for candidate compounds suitable for use in such treatments are also provided.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Biomarkers for bipolar disorder include Cer(d18:0/24:1), TG(18:1_38:5), TrpBetaine, PC ae C36:5, 3-IAA, Lac, PC aa C32:3, GCA, Asn, TMAO, 3-IPA, t4-OH-Pro, TG(17:1_36:3), SM (OH) C14:1, SM C20:2, PC aa C42:0, and HexCer(d18:1/22:0). Levels of the biomarkers can be measured in samples taken from patients for use in methods of diagnosis of bipolar disorder or a predisposition to bipolar disorder, or for prognosing the development of bipolar disorder, or for monitoring efficacy of a therapy in an individual having, suspected of having, or being predisposed to bipolar disorder.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

322).

IPC Classes  ?

• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

The present invention relates to a semi-crystalline polymeric material, preferably for a thermoelectric device, the material comprising a first conjugated polymer, a second conjugated polymer blended with the first conjugated polymer, and a dopant, wherein the second conjugated polymer has a number average molecular weight which is 25% greater or more than the first conjugated polymer. A method of preparing a semi-crystalline polymeric material, the use of the semi-crystalline polymeric material and a thermometric device comprising the semi-crystalline polymeric material are also described.

IPC Classes  ?

• H10N 10/856 - Thermoelectric active materials comprising organic compositions
• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers

Abstract

A process of making an adsorbent body, wherein the process includes the steps of: (a) contacting adsorbent material with an initial mixture to form a solvated adsorbent mixture in a first solvent; (b) removing the first solvent and removing at least some of the first solvent from the solvated adsorbent mixture in the first solvent to form an initial adsorbent body; (c) contacting the initial adsorbent body with a second solvent to form a reduced-binder adsorbent body in a second solvent; and (d) solvent-drying the reduced-binder adsorbent body to form the adsorbent body. Also described is an adsorbent body, and the use of the adsorbent body in gas storage.

IPC Classes  ?

• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• F17C 11/00 - Use of gas-solvents or gas-sorbents in vessels

Abstract

This invention provides a nucleic acid construct comprising; (i) a first nucleotide sequence for expression, (ii) a first promoter operably linked to the first nucleotide sequence, said first promoter being inducible, (iii) a first insulating sequence located upstream of the first nucleotide sequence and first promoter, (iv) a second insulating sequence located downstream of the first nucleotide sequence and first promoter, (v) a second nucleotide sequence encoding a transcription regulator protein that induces expression from the first promoter; and (vi) a second promoter operably linked to the second nucleotide sequence. The second nucleotide sequence and second promoter may be located either (a) upstream of the first insulating sequence or (b) downstream of the second insulating sequence. Also provided are vectors and mammalian cells comprising the construct, methods of inducibly expressing a nucleotide sequence in the construct, and methods of producing a mammalian cell by inducing expression from the construct.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A method of converting a semi-conducting phase of a layered transition metal-based material to a metallic phase. The method comprises treating the semi-conducting phase with light of photon energy that is greater than a bandgap of the semi-conducting phase in the presence of a reducing agent. Also disclosed are methods of phase patterning a layered transition metal-based material and layered transition metal-based materials obtained or obtainable by the methods disclosed. The layered transition metal-based material can be a transition metal dichalcogenide.

IPC Classes  ?

• H01L 21/428 - Bombardment with radiation with high-energy radiation using electromagnetic radiation, e.g. laser radiation
• H01L 21/44 - Manufacture of electrodes on semiconductor bodies using processes or apparatus not provided for in groups

Abstract

There is provided a superconducting electromagnet in a form similar to a Bitter magnet. In certain forms, the electromagnet may comprise a plurality of discs formed from superconducting material. Each disc may have a central through-hole and a slit between the through-hole and an outer circumference. The discs may be arranged in a coaxial stack with the slits being azimuthally offset. The discs may be conductively connected by a conducting joint aligned azimuthally between slits of adjacent discs so that the coaxial stack forms a helical conducting path. The discs may be formed from a crystalline ceramic superconductor, for example a cuprate or (RE)BCO.

IPC Classes  ?

• H10N 60/20 - Permanent superconducting devices
• H01B 12/02 - Superconductive or hyperconductive conductors, cables or transmission lines characterised by their form
• H10N 60/00 - Superconducting devices
• H10N 60/01 - Manufacture or treatment
• H10N 69/00 - Integrated devices, or assemblies of multiple devices, comprising at least one superconducting element covered by group

Abstract

The invention provides methods of performing single cell RNA sequencing, methods of designing or providing a composition for performing single cell RNA sequencing, methods of analysing single cell RNA sequencing data, and related systems and products The single cell RNA sequencing method comprises obtaining a sequencing library and comprises using a plurality of target-specific capture reagents associated with a respective plurality of target transcripts, to enrich the sequencing library for cDNA molecules corresponding to the plurality of target transcripts, wherein the concentration of a first target-specific capture reagent for a first target transcript is different from the concentration of a second target-specific capture reagent for a second target transcript.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing

Abstract

The present invention relates to a pharmaceutical composition comprising nanoparticles of a cyanine dye and a therapeutic agent. The present invention also relates to the use of said pharmaceutical composition in therapy.

IPC Classes  ?

• A61K 9/51 - Nanocapsules

Abstract

The present invention provides biomarkers and methods useful for screening for risk of progression to invasive ductal carcinoma (IDC) in a patient.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

Abstract

A method of characterising a DNA sample obtained from a tumour, the method including the steps of: (a) obtaining a tumour copy number profile for the sample, (b) quantifying a set of copy number features of the copy number profile, and (c) determining exposure to one or more signatures of chromosomal instability based on the quantified features. A copy number feature is a metric that characterises a copy number event in a copy number profile. The set of features does not comprise the absolute copy number of segments in the copy number profile. The signatures of chromosomal instability have been obtained by quantifying the set of copy number features in a plurality of tumour samples, and identifying one or more mutational signatures likely to result in the copy number profiles of the plurality of tumour samples. Methods of characterising types of chromosomal instability present in samples, providing a prognosis, identifying a drug target, or identifying a therapy for a subject are also described.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 40/20 - Supervised data analysis
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to sensors for detecting the presence or measuring the concentration of a target analyte, the sensor comprising: (i) a first phase comprising a first crosslinked polymer: (ii) a second phase comprising a second crosslinked polymer: and (ill) a target analyte recognition agent: the first phase and second phase arranged to form an optical grating. The first crosslinked polymer comprises low amounts of a crosslinking agent. The present invention also relates to methods of making a sensor for detecting the presence or measuring the concentration of a target analyte.

IPC Classes  ?

• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator

Abstract

Transgenic rodents and rodent cells that express components of the human immune system, and their uses in generating human T cell receptors (TCRs). A genetically modified rodent comprising a TCR alpha gene locus comprising unrearranged human TCR alpha variable gene segments and a human TCR alpha constant region, and a TCR beta gene locus comprising unrearranged human TCR beta variable gene segments and a human TCR beta constant region. Use of hTCR transgenic rodents to generate antigen-specific CD8+ T cell responses for the discovery of fully human TCR sequences with therapeutic potential.

IPC Classes  ?

• A01K 67/0276 - Knock-out vertebrates
• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• C07K 14/725 - T-cell receptors
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/74 - Major histocompatibility complex [MHC]

Abstract

A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to methods of working sheet metal and an apparatus. Methods include providing a sheet metal workpiece having first and second surfaces opposed to each other and at least one edge, bending the workpiece to form at least a first sidewall portion, the first sidewall portion thereby defining a curved fold region in the sheet metal workpiece adjacent the first sidewall portion. The first anvil tool and a first forming tool are provided for contact with and constraint of the first and second surfaces of the sheet metal workpiece respectively. The forming tool and/or anvil tool are then slid along the curved fold region to cause shear material transfer in the curved fold region to further deform the curved fold region. Methods can allow for formation of components of similar shape as made at present by deep drawing methods, but with less wastage of the starting material.

IPC Classes  ?

• B21D 19/04 - Flanging or other edge treatment, e.g. of tubes by continuously-acting tools moving along the edge shaped as rollers
• B21D 5/01 - Bending sheet metal along straight lines, e.g. to form simple curves between rams and anvils or abutments
• B21D 5/06 - Bending sheet metal along straight lines, e.g. to form simple curves by drawing procedure making use of dies or forming-rollers, e.g. making profiles
• B21D 5/08 - Bending sheet metal along straight lines, e.g. to form simple curves by drawing procedure making use of dies or forming-rollers, e.g. making profiles making use of forming-rollers
• B21D 22/16 - Spinning over shaping mandrels or formers
• B21D 31/00 - Other methods for working sheet metal, metal tubes, metal profiles

Abstract

222 in the first fluid; (ii) the heat transfer component is configured to transfer thermal energy between the first reaction vessel and a third fluid (6); and (iii) the second reaction vessel is configured to accept the third fluid from the heat transfer component.

IPC Classes  ?

• B01D 53/34 - Chemical or biological purification of waste gases
• B01D 53/62 - Carbon oxides

Abstract

A method for autofocusing an object at a microscope, the method comprising: receiving, using a beam splitter, a portion of light from the object at a camera and receiving a remaining portion of the light at a sensor; capturing one or more images of the object at the sensor wherein the sensor is inclined with respect to the orthogonal image plane, further wherein the one or more images have a region of the highest level of focus, such that movements of the object result in a change of location of the region of the highest level of focus in the one or more images captured at the sensor; capturing one or more images of the object at the camera; determining a location of the region of the highest level of focus in the one or more images captured at the sensor; and restoring the image plane of the object to the camera by adjusting a refocusing device, positioned between the object and the beam splitter, wherein the restoring is based on the determined location of the region of the highest level of focus on the sensor.

IPC Classes  ?

• G02B 21/24 - Base structure

Abstract

A process for the production of a material agglomerate is described. The process comprises: (a) providing a temperature-controlled flow-through reactor; (b) introducing a flow of metal catalyst or metal catalyst precursor into the temperature-controlled flow-through reactor; (c) introducing a flow of a source of production material into the temperature-controlled flow-through reactor; (d) operating the source of thermal energy to expose the metal catalyst or metal catalyst precursor and source of production material to a temperature in a reaction zone of the flow-through reactor that is sufficient to generate particulate metal catalyst and to produce a production material precursor; (e) displacing the production material precursor as a continuous discharge through a discharge outlet of the temperature-controlled flow-through reactor; (f) collecting the continuous discharge. The method is characterised in that the source of thermal energy comprises a heat source within the flow through volume spaced apart from the reactor wall, the said heat source providing at least a major part of the thermal energy to raise the temperature of materials in the reaction zone of the flow-through reactor. An apparatus for performing the method is also described.

IPC Classes  ?

• C01B 32/162 - Preparation characterised by catalysts
• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
• C01B 32/164 - Preparation involving continuous processes
• D01F 9/127 - Carbon filamentsApparatus specially adapted for the manufacture thereof by thermal decomposition of hydrocarbon gases or vapours
• D01F 9/133 - Apparatus therefor
• B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The present invention relates to CDK4/6 inhibitor for use in the treatment of neuroblastoma, wherein the CDK4/6 inhibitor is administered in combination with retinoic acid and wherein said neuroblastoma comprises adrenergic (ADRN)-type neuroblastoma cells and associated methods.

IPC Classes  ?

• A61K 31/203 - Retinoic acids
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

A method for the detection or prognosis of cancer and/or metastasis is provided. Tumour samples may be used to determine the presence of a mutation within the sodium leak channel (NALCN). A risk score of cancer and/or metastasis can be determined based on if the mutation causes a reduction in the pore size of NALCN. A computational model, a composition, and a kit are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

There is provided a compound of formula I for use in a method for treating or preventing a synucleinopathy disease, the method comprising administering to a subject, a therapeutically effective amount of said compound (I): or a pharmaceutically acceptable salt or hydrate thereof.

IPC Classes  ?

• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

There is provided a system for the production of ammonia, the system comprising: a reservoir for liquid ammonia or water; a first vessel configured to receive gaseous nitrogen and hydrogen feedstocks, the first vessel comprising an ammonia Core process synthesis catalyst and a first material for storing ammonia, a second vessel adjacent and in direct thermal communication with the first vessel, the second vessel comprising a second material for storing ammonia or water, and being in fluid communication with the reservoir for liquid ammonia or water; a third vessel comprising a third material for storing ammonia and comprising an outlet for recovering ammonia; wherein the system has at least two operating modes, wherein: (i) in a first operating mode for retaining ammonia synthesised on the catalyst the first vessel is not in fluid communication with the third vessel, and (ii) in a second operating mode the first vessel is in fluid communication with the third vessel for passing ammonia to the third material.

IPC Classes  ?

• C01C 1/04 - Preparation of ammonia by synthesis
• C01C 1/00 - AmmoniaCompounds thereof
• F17C 11/00 - Use of gas-solvents or gas-sorbents in vessels

Abstract

The invention provides a method for cleaving a target nucleic acid molecule. The method comprises contacting the target nucleic acid molecule with a bifunctional molecule of formula (I), C-L-B, where —C is a cleavage group that is imidazole, optionally substituted with 1 to 3 C1-6 alkyl groups, -L- is a linker and —B is a non-covalent binding group, such that the bifunctional molecule non-covalently binds to the target nucleic acid molecule, and allowing the bifunctional molecule to cleave the target nucleic acid molecule bound thereto. The invention also provides a method of identifying a secondary or tertiary structure within a target nucleic acid, as well as a bifunctional molecule and a bifunctional molecule for use in a method of treatment.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The disclosure relates to the design and preparation of a luminescent polymer film and in particular, to improve the efficiency of photovoltaic (PV) cells under diffuse lighting conditions and methods of making and uses thereof.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H01L 31/055 - Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means where light is absorbed and re-emitted at a different wavelength by the optical element directly associated or integrated with the PV cell, e.g. by using luminescent material, fluorescent concentrators or up-conversion arrangements

Abstract

The present invention relates to an in vitro human embryo organoid at a post-gastrulation stage of development. Methods of forming the organoid and derivatives therefrom are described as well as their uses. The in vitro human embryo organoid at a post-gastrulation stage of development demonstrates early human development that recapitulates the formation of three germ layers, and hPGCLCs without exogenous BMP signalling.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

A combination of a first metal oxide and a second metal oxide, wherein the second metal oxide is a mixed ionic-electronic conductor.

IPC Classes  ?

• C01G 49/00 - Compounds of iron
• C01B 3/06 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents

Abstract

A fan assembly comprising: a fan having a central axis; a diffuser having an inlet and an outlet; one or more splitters located within the diffuser, the one or more splitters extending circumferentially around the central axis of the fan and being positioned between the fan and the outlet of the diffuser; wherein the diffuser comprises an outer wall and a central hub, the outer wall extending circumferentially around the central axis of the fan and the central hub being arranged coaxially with the central axis of the fan, the cross-sectional area of the diffuser between the central hub and the outer wall being greater at the outlet of the diffuser than at the inlet of the diffuser.

IPC Classes  ?

• F04D 19/00 - Axial-flow pumps specially adapted for elastic fluids
• F04D 29/54 - Fluid-guiding means, e.g. diffusers
• F04D 17/06 - Helico-centrifugal pumps
• F04D 19/02 - Multi-stage pumps
• F04D 29/58 - CoolingHeatingDiminishing heat transfer
• H02K 9/06 - Arrangements for cooling or ventilating by ambient air flowing through the machine having means for generating a flow of cooling medium with fans or impellers driven by the machine shaft

Abstract

An apparatus for the generation of nanoparticles in the gas phase from a metalorganic precursor is described. The apparatus comprises: a reaction chamber defining a reaction volume; an electrode arrangement including an electrode located within the reaction volume and operable to generate a DC corona discharge at a discharge site therein; a first flow generator operable to generate a first gas flow at a first volumetric flow rate in a first flow direction towards and through the discharge site; a second flow generator operable to generate a second gas flow of a metalorganic precursor in a carrier gas at a second volumetric flow rate in a second flow direction such as to intercept the first gas flow at a location in the reaction chamber downstream of the discharge site; wherein the first volumetric flow rate is higher than the second volumetric flow rate. A method for the generation of nanoparticles in the gas phase from a metalorganic precursor is also described.

IPC Classes  ?

• B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor
• B01J 19/14 - Production of inert gas mixturesUse of inert gases in general
• B01J 4/00 - Feed devicesFeed or outlet control devices

Abstract

A system comprising: a first vessel configured to convert a first fluid into a second fluid, and a second vessel configured to convert the second fluid into a third fluid, wherein: the first vessel comprises an output which is coupled to an input of the second vessel, and the first fluid comprises: a carbon containing compound, a hydrogen containing molecule that is not a hydrocarbon, or a combination of a carbon containing compound and a hydrogen containing molecule that is not a hydrocarbon.

IPC Classes  ?

• C01B 3/34 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents
• B01D 53/86 - Catalytic processes
• C01B 32/50 - Carbon dioxide

Abstract

According to a first aspect of the disclosure, there is provided a computer implemented method of quantifying interactions between constituents of a bio-molecular system that exhibits phase separation into binary first and second phases in certain conditions, comprising: receiving input data, the input data comprising data describing the bio- molecular system in a plurality of different conditions, differing in at least two parameters, the parameters including the concentration of at least one constituent bio-molecule within the bio-molecular system, wherein for each of the different conditions, the input data comprises data describing the at least two parameters, and the concentration of at least a first of the at least one constituents in the first phase and/or the second phase; determining, based on the input data, a concentration boundary between a first set of data substantially comprising data for which the concentration of the first constituent in the first phase is above a threshold value, and a second set of data substantially comprising data for which the concentration of the first constituent in the first phase is below the threshold value; determining a gradient of the concentration boundary for the concentration of the first constituent with respect to at least one other of the at least two parameters, wherein the gradient corresponds to a portion of the concentration boundary corresponding to a subset of the first set of data and the second set of data that forms part of a third set of data substantially comprising data for conditions in which both the first and second phases are present; and determining, based on the gradient, a stoichiometric parameter quantifying interactions between constituents of the bio-molecular system.

IPC Classes  ?

• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

A steering assembly comprising a pair of wheels and a moveable steering linkage, the wheels being mounted at either end of the moveable steering linkage; wherein each wheel is provided with a brake, each brake independently actuatable such that a different braking torque may be selectively applied to each wheel so as to induce a yawing moment across the moveable steering linkage, thereby causing the wheels to steer.

Abstract

The invention relates to methods for nucleic acid characterisation. In particular, the method of the invention relates to methods for characterising target nucleic acids in a sample.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a lithium sulfur cell, a method of preparing a lithium sulfur cell, and a battery comprising the lithium sulfur cell. The lithium sulfur cell comprises a working electrode comprising a film comprising stacked layers of a metallic phase transition metal dichalcogenide of formula (I): LiaMX2 where a is from 0.0 to 2.0, X is selected from S, Se and Te, and M is a transition metal, such as Ti, Hf, V, Nb, Ta, Mo, W, Tc, Re, Pd or Pt. The method of preparing a lithium sulfur cell comprises: exfoliating a transition metal dichalcogenide to provide a metallic phase. transition metal dichalcogenide of formula (I); assembling a working electrode comprising a film comprising stacked layers of the metallic phase transition metal dichalcogenide and sulfur or a lithium (poly) sulfide: and assembling a lithium sulfur cell comprising the working electrode, a counter electrode, and an electrolyte.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 10/052 - Li-accumulators
• H01M 10/44 - Methods for charging or discharging

Abstract

According to the present disclosure there is provided a method of depositing a fibre onto a freestanding object using a fibre deposition apparatus. The fibre deposition apparatus comprises a dispenser and a moveable arm defining a deposition zone. The method comprises: positioning the fibre deposition apparatus such that the freestanding object is located within the deposition zone, forming a droplet of a fibre-forming liquid composition at an outlet of the dispenser, moving the arm from a first position in contact with the droplet to a second position away from the first position so as to draw the droplet into a drawn fibre, and depositing the drawn fibre onto the freestanding object as the arm moves from the first position to the second position. According to a further aspect of the present disclosure there is provided a fibre deposition apparatus for depositing fibres onto a freestanding object. According to a further aspect of the present disclosure there is provided a liquid composition for forming a drawn fibre. The liquid composition comprises a fibre-forming polymer; a solvent; and a functional component.

IPC Classes  ?

• D01D 1/02 - Preparation of spinning solutions
• D01D 4/02 - Spinnerettes
• D04H 1/42 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
• D04H 1/4374 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece using different kinds of webs, e.g. by layering webs
• D01D 5/04 - Dry spinning methods
• D01D 5/00 - Formation of filaments, threads, or the like
• D01D 1/06 - Feeding liquid to the spinning head
• D04H 1/736 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged characterised by the apparatus for arranging fibres
• D04H 1/76 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres otherwise than in a plane, e.g. in a tubular way
• D04H 1/74 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being orientated, e.g. in parallel

Abstract

According to a first aspect of the disclosure there is provided a data collection device for monitoring a physiological state of a subject, comprising: a plurality of sensors, each of the plurality of sensors being configured to obtain a biophysical signal from the subject; a flexible substrate configured to be placed against the subject by a user and configured to flex to substantially conform with the form of the subject; wherein the plurality of sensors are connected to the substrate and arranged such that each sensor is configured to move relative to each other sensor to enable the substrate to flex to substantially conform to the form of the subject.

IPC Classes  ?

• A61B 7/00 - Instruments for auscultation
• A61B 7/02 - Stethoscopes

Abstract

The present application relates to a metal organic framework (MOF) glass composite comprising metal halide perovskite, and a method for its preparation.

IPC Classes  ?

• C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C09K 11/61 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing fluorine, chlorine, bromine, iodine or unspecified halogen elements

Abstract

TT-space to find a global optimum for the spoke locations.

IPC Classes  ?

• G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux
• G01R 33/46 - NMR spectroscopy
• G01R 33/54 - Signal processing systems, e.g. using pulse sequences
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
• G01R 33/28 - Details of apparatus provided for in groups

Abstract

In a method for preparing a hyperpolarised sample, for example for a magnetic resonance procedure, a starting solution comprising alpha-ketoglutaric acid and 13C-labelled molecules is frozen to form a frozen solution. The solution is irradiated with ultraviolet and/or visible radiation, to generate free radicals. The frozen solution is then hyperpolarised by applying a magnetic field to the solution while irradiating it with frequency-modulated microwave radiation.

IPC Classes  ?

• A61K 49/10 - Organic compounds
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes

Abstract

In a method for preparing a hyperpolarised sample, for example for carrying out a magnetic resonance technique, the sample is formed as a frozen layer (4) of a starting solution on a surface of a thermoconductive sample holder (1,2). The solution comprises molecules for hyperpolarisation, and photo-reactive molecules. Free radicals are induced in the frozen layer by exposing it to radiation. The sample is then hyperpolarised by dynamic nuclear polarization at a dynamic nuclear polarization temperature. After hyperpolarisation, the temperature of the sample is raised to a thermalisation or quenching temperature by thermal conduction of heat through the sample holder, to quench the free radicals. The polarised sample may then be stored for use, retaining its polarisation.

IPC Classes  ?

• G01R 33/28 - Details of apparatus provided for in groups
• G01N 1/28 - Preparing specimens for investigation
• G01N 1/42 - Low-temperature sample treatment, e.g. cryofixation
• G01N 1/44 - Sample treatment involving radiation, e.g. heat
• G01R 33/30 - Sample handling arrangements, e.g. sample cells, spinning mechanisms

Abstract

Devices and methods for wireless patient monitoring are described. A receiver connectable to a patient monitor comprises a processor and circuitry coupled to the processor. The circuitry is configured to wirelessly receive data based on an output from a pulse oximeter unit, wherein the data comprises a first data set comprising voltage values corresponding to a photodiode current sensed responsive to a first LED of the pulse oximeter unit, and a second data set comprising voltage values corresponding to a photodiode current sensed responsive to a second LED of the pulse oximeter unit. The circuitry is further configured to generate a signal based on the received data, wherein the signal is configured to emulate a wired connection input signal to the patient monitor, and output the generated signal to the patient monitor.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/319 - Circuits for simulating ECG signals

Abstract

This invention relates to methods for detecting the presence or absence of target nucleic acids in samples by excising and detecting specific target probes.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• C12Q 1/6825 - Nucleic acid detection involving sensors
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Provided is a condensation particle counter for measuring the concentration of particles in a flow of a sample aerosol. The condensation particle counter comprises: a sample inlet (10), a growth passage (20) defined by one or more sidewalls and configured to receive an axial flow of a sample aerosol from the sample inlet (10), and a condensation section (22) through which the growth passage (20) extends. The condensation section (22) is configured to condense vapour onto particles in the sample aerosol to form droplets. Also provided is a condensation particle counter wherein the growth passage (20) is defined by a gas-permeable sidewall (23) and the condensation particle counter is configured to provide an inward flow of sheathing gas through the gas permeable sidewall (23), said inward flow including a radial component. Also provided is a condensation particle counter comprising a droplet counting unit having a first optical head (70) configured to emit laser light into the flow of sample aerosol and detect backscattered light therefrom to identify droplets in the flow of sample aerosol using self-mixing interferometry.

IPC Classes  ?

• G01N 15/06 - Investigating concentration of particle suspensions

Abstract

The invention provides modified therapeutic mRNAs that include at least one nucleic acid sequence selected from at least one frameshifting nucleic acid sequence, at least one ribosomal slippery sequence, and/or at least one alternative reading frame sequence wherein the nucleic acid sequence includes at least one synonymous mutation. Also provided are methods of producing said modified therapeutic mRNAs, methods of reducing off-target immunogenicity to a therapeutic mRNA, and methods of reducing out-of-frame translation and/or increasing translation fidelity of a therapeutic mRNA. Further provided are said modified therapeutic mRNAs for use as medicaments.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/67 - General methods for enhancing the expression

Abstract

Designed coronavirus polypeptide sequences are described, and their use as vaccines against viruses of the coronavirus family. The designed sequences include designed coronavirus spike (S) proteins and fragments thereof, including CoV_S_T2_35 (SEQ ID 5 NO:1), CoV_S_T2_36 (SEQ ID NO:2), and Omicron_vaccine (SEQ ID NO:3). Variants of CoV_S_T2_35 (deom) are also described, including COV_S_T3_1 (SEQ ID NO:31) and COV_S_T3_2 (SEQ ID NO:32), and fragments thereof. Nucleic acid molecules encoding the polypeptides, vectors, fusion proteins, pharmaceutical compositions, cells, and their use as vaccines against viruses of the coronavirus family are also described.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to the field of brain tumour treatment. The invention provides methods of killing brain tumour cells in these tissues using high concentrations of cytotoxic agents which are capable of binding strongly to normal brain extracellular matrix (ECM), but less strongly to extracellular matrix components in the tumour environment. The cytotoxic agent is a polyamine, e.g. spermidine or putrescine.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 31/722 - ChitinChitosan
• A61K 31/785 - Polymers containing nitrogen
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to polypeptides that are resistant to degradation in the gastrointestinal tract and that bind to a target (i.e. a target ligand). In particular, it provides a mutant Kunitz-type soybean trypsin inhibitor (SBTI) family polypeptide comprising two or more amino acid mutations compared to the corresponding unmutated (e.g. wild-type) SBTI family polypeptide, wherein the mutant SBTI family polypeptide comprises: (i) one or more amino acid mutations in a first domain corresponding to positions 22-25 of SEQ ID NO: 1; and (ii) one or more amino acid mutations in a second domain corresponding to positions 47-50 of SEQ ID NO: 1, wherein the mutant SBTI family polypeptide: (a) binds selectively to a ligand that does not bind to the corresponding unmutated (e.g. wild-type) SBTI family polypeptide; and (b) is resistant to cleavage by pepsin.

IPC Classes  ?

• C07K 14/81 - Protease inhibitors
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Abstract

A method of conditioning a SES substrate comprises providing a support and providing a nanoparticle layer on the support. The nanoparticle layer comprises metallic nanoparticles. The nanoparticle layer is subjected to an oxidative cleaning step, thereby producing an oxide coating at the surfaces of the nanoparticles. Subsequently, the nanoparticle layer is subjected to a redefinition step, wherein the oxide coating is removed in the presence of scaffolding ligands so that the scaffolding ligands are arranged between adjacent nanoparticles to define their relative spacing for subsequent use in SES analysis. The SES may be SERS or SEIRA. Also disclosed are methods for carrying out SES analysis.

IPC Classes  ?

• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• G01N 21/65 - Raman scattering
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

A method of determining diffusion coefficient of one or more components in a polydisperse sample is provided. The method comprising the steps of: introducing an auxiliary fluid flow into a fractionation channel; introducing the polydisperse sample comprising one or more components into the fractionation channel; allowing the sample and the auxiliary fluid to create a combined flow; fractionating the combined flow into two or more fractions by diffusive sizing; subsequently separating two or more components from each fraction by creating a distribution of the components within a separation channel; detecting a characteristic of each the two or more components in each fraction; and comparing the characteristic of each component in each fraction in order to determine the diffusion coefficient of each of the one or more components in the polydisperse sample.

IPC Classes  ?

• G01N 33/561 - Immunoelectrophoresis
• G01N 13/00 - Investigating surface or boundary effects, e.g. wetting powerInvestigating diffusion effectsAnalysing materials by determining surface, boundary, or diffusion effects
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/05 - Dipeptides
• A61K 38/06 - Tripeptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 207/26 - 2-Pyrrolidones
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

Method of synthesising magnesium nanoparticles, and magnesium nanoparticles A method of synthesising magnesium nanoparticles is provided. The method comprises mixing a magnesium precursor with a reducing agent to induce nucleation of Mg nanoparticles. The reducing agent contains a cationic content and a polycyclic aromatic content, and the polycyclic aromatic content of the reducing agent comprises at least 10% polycyclic aromatic dianion. A magnesium nanoparticle, and a powder or a suspension, are also disclosed.

IPC Classes  ?

• B22F 1/054 - Nanosized particles
• B22F 1/0545 - Dispersions or suspensions of nanosized particles
• B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
• C22C 1/04 - Making non-ferrous alloys by powder metallurgy
• C22C 23/00 - Alloys based on magnesium

Abstract

Methods of manufacturing polyoxotitanates, polymer-polyoxotitanate composite materials and novel polyoxotitanates are provided. The invention enables spectral conversion of sunlight towards longer wavelengths, which is beneficial for increasing 5 available photons for photosynthesis.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals

Abstract

A process is disclosed for the combined manufacture of steel and cement clinker. Steel scrap is loaded in an electric arc furnace for forming molten steel. Cement paste derived from construction and demolition waste is loaded in the electric arc furnace to act as a flux for the steel to assist in the removal of impurities from the molten steel and forming an electric are furnace slag. The heat of the molten steel promotes clinkering of the electric are furnace slag to form clinkered electric arc furnace slag. The clinkered electric arc furnace slag is removed from the electric arc furnace.

IPC Classes  ?

• C21C 5/54 - Processes yielding slags of special composition
• C04B 7/19 - Portland cements
• C04B 18/06 - Combustion residues, e.g. purification products of smoke, fumes or exhaust gases
• C21C 5/52 - Manufacture of steel in electric furnaces

Abstract

The present invention provides devices and methods for electroporation. Embodiments of the invention provide an electroporation device, the device having: a microfluidic channel with a fluid inlet and a fluid outlet; and a pair of interdigitated electrodes formed within said channel, wherein said electrodes are coated with PEDOT:PSS on a contact surface which is in contact with fluid in the channel. Other embodiments of the invention provide a method of performing electroporation on cells in a sample, the method including the steps of: introducing the sample into a chamber having a pair of electrodes each having a coating of PEDOT:PSS on a contact surface which is in contact with the sample; and applying oscillating stimulation voltage signals to the sample using the electrodes, wherein the stimulation voltage signals are applied so as to stimulate electroporation in the cells.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

in vitroin vivoin vivo. In some aspects, disclosed are methods of producing these non-natural human chondrocytes. In further aspects, disclosed are methods of using these non-natural human chondrocytes, such as for promoting cartilage growth and/or repair.

IPC Classes  ?

• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

In general terms this invention relates to a charged sorbent material. In particular, though not exclusively, this invention relates to a charged sorbent material comprising a porous carbon material and charged non-carbon particles within the pores of the porous carbon material. The invention also relates to a method of making a charged sorbent material, and a process of removing an adsorbate from a fluid by contacting it with the charged sorbent material.

IPC Classes  ?

• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01D 53/62 - Carbon oxides
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 20/34 - Regenerating or reactivating

Abstract

This invention relates to a method for codon optimising a target nucleic acid sequence for expression in a host cell. The invention also relates to codon optimised nucleic acids for improved expression in a host cell, and to vectors and host cells comprising codon optimised nucleic acids.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/074 - Adult stem cells
• C12N 9/22 - Ribonucleases

Abstract

Designed messenger RNAs (mRNAs) encoding coronavirus polypeptides are described, as well as mRNA vaccine vectors, pharmaceutical compositions comprising the mRNAs or vectors, and mRNA vaccines, and their use to induce an immune response against viruses of the coronavirus family. The designed sequences include mRNA sequences encoding designed coronavirus receptor binding domain (RBD) sequences CoV_S_T2_17, CoV_S_T2_17 comprising a transmembrane domain sequence (CoV_S_T2_20), CoV_S_T3_3 (T2_20v2), and CoV_S_T3_4 (T2_17_T2_20 dimer). Polypeptides, nucleic acid molecules encoding the polypeptides, vectors, fusion proteins, pharmaceutical compositions, and their use as vaccines against viruses of the coronavirus family are also described.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides a computer-implemented method for analysing a urine sample from a subject. The method comprises providing the value of one or more cell-free DNA fragment size metrics for said sample, and determining whether the sample has a high or low likelihood of being from a brain cancer patient by providing said values of said cell-free DNA fragment size metrics as input to a machine learning model. The machine learning model is trained to classify sample data into one of at least two classes, the at least two classes comprising a first class having a high likelihood of being from a brain cancer patient and a second class having a low likelihood of being from a brain cancer patient. Methods for diagnosing or screening for brain cancer, detecting recurrence or residual disease, providing a prognosis or selecting a treatment for brain cancer are also described.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/20 - Supervised data analysis

Abstract

Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, Q, Ra, Rb, Rc, Rd and Re are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines

Abstract

The present invention relates to synthetic polypeptide compounds which bind to a class A G-protein-coupled receptor, the Apelin receptor. These compounds may act as apelin receptor antagonists. These compounds and compositions comprising them may be useful in the treatment of diseases, such as cancer.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Disclosed is a method for analyzing a set of images of a coronary artery tissue. The method comprises segmenting the images for the presence of normal artery features and those associated with OCT, correcting artifacts, and optimizing the images. The method further comprises segmenting the diseased tissue into distinct tissue types, and measuring features of interests of the segmented tissue types. The method further comprises compiling a first set of measurements for each identified feature of interest at a first time, and a second set of measurements at a second time subsequent to the first time. The method further comprises determining changes in the coronary artery tissue, indicative of progression or regression of a diseased state, or prediction of multiple adverse cardiovascular events (MACE) such as cardiac death or myocardial infarction.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 5/20 - Image enhancement or restoration using local operators
• G06T 5/40 - Image enhancement or restoration using histogram techniques
• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks
• G06T 7/11 - Region-based segmentation
• G06T 7/13 - Edge detection
• G06T 7/136 - SegmentationEdge detection involving thresholding
• G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
• G06V 10/32 - Normalisation of the pattern dimensions
• G06V 10/36 - Applying a local operator, i.e. means to operate on image points situated in the vicinity of a given pointNon-linear local filtering operations, e.g. median filtering
• G06V 10/54 - Extraction of image or video features relating to texture
• G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention provides a method for identifying a modified cytosine residue, which may be 5-methylcytosine or 5-hydroxymethylcytosine, in a nucleotide sequence. The method comprises oxidising the modified cytosine residue through a non-enzymatic, one-electron process to form 5-formylcytosine. The presence of 5-formylcytosine can be established by labelling and identifying this residue. The invention also provides a method of modifying a polynucleotide containing a 5-methylcytosine and/or a 5-hydroxymethylcytosine residue, a method of oxidising 5-methylcytosine, 5-hydroxymethylcytosine, a 5-methylcytosine residue, or a 5-hydroxymethylcytosine residue, use of a non-enzymatic radical initiator to oxidise a 5-methylcytosine or 5-hydroxymethylcytosine residue, and a kit for use in the methods.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6869 - Methods for sequencing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

This invention related to methods of adapting or modifying a complementary DNA (cDNA) sequence for expression in a eukaryotic cell. A nucleic acid molecule is provided that comprises a cDNA sequence that includes two or more splicing consensus motifs that divide the cDNA sequence into exon regions of 50 to 1200 nucleotides. Heterologous introns are then inserted into the splicing consensus motifs of the cDNA sequence, wherein each heterologous intron comprises a 3′ region having a GC content that is equal to or lower than the GC content of a 5′ region of the immediately downstream exon region. This produces a nucleic acid molecule comprising a modified cDNA sequence for expression in a eukaryotic cell. Methods, recombinant nucleic acid comprising a cDNA sequence, expression vectors comprising the recombinant nucleic acid and eukaryotic cells comprising a recombinant nucleic acid or expression vector are provided.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The present application features methods of treating schizophrenia and bipolar disorder by targeting dysregulated novel open reading frames (nORF) in which increased or reduced expression of the dysregulated nORF is associated with the schizophrenia or bipolar disorder.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a method for upcycling plastic waste comprising: (i) contacting a plastic from said plastic waste with an enzyme to degrade said plastic to provide a composition comprising monomers and/or oligomers, and/or derivatives therefrom, of said plastic; and (ii) photoreforming said composition to produce a mixture of products comprising hydrogen gas and oxidation products of said monomers and/or oligomers, and/or derivatives therefrom.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation

Abstract

The present invention relates to compositions for use in treating or preventing ischaemia reperfusion injury. In particular, the present invention relates to a composition comprising a salt of formula (I): for use in treating or preventing ischaemia reperfusion injury in a subject; wherein said composition has a pH of from about 4.0 to about 7.0. and wherein X, Y, n, m, Z, A and B are as defined herein. The present invention relates to compositions for use in treating or preventing ischaemia reperfusion injury. In particular, the present invention relates to a composition comprising a salt of formula (I): for use in treating or preventing ischaemia reperfusion injury in a subject; wherein said composition has a pH of from about 4.0 to about 7.0. and wherein X, Y, n, m, Z, A and B are as defined herein.

IPC Classes  ?

• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to novel compounds of formula (I) defined herein that are suitable for the non-enzymatic cleavage of target nucleic acids. The present invention also relates to the pharmaceutical compositions comprising these compounds and to the use of these compounds in, for example, epigenomic and epitranscriptomic mapping, as well as in therapy, such as anti-microbial and/or anti-viral therapy.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

The present invention relates to novel compounds of formula (I) defined herein that are suitable for the non-enzymatic cleavage of target nucleic acids. The present invention also relates to the pharmaceutical compositions comprising these compounds and to the use of these compounds in, for example, epigenomic and epitranscriptomic mapping, as well as in therapy, such as anti-microbial and/or anti-viral therapy.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents

Abstract

A computer-implemented method for sampling data from a measurement device for representing uncertainty in measurements made by the measurement device, the method comprising: obtaining a data set comprising time-sequential data elements generated by the measurement device; and: (a) calculating a statistic of a sub-set of data elements consecutive within the data set; (b) comparing the value of the statistic to a reference value; and, (c) if the value of the statistic differs from the reference value by less than a threshold amount, then: modifying the sub-set by appending to the sub-set at least one additional data element which is subsequent to the sub-set; and, repeating steps (a) to (c) for the modified sub-set of data elements; (d) if the value of the statistic differs from the reference value by more than said threshold amount, then: outputting the sub-set collectively as a sample set of data elements generated by the measurement device for representing uncertainty in measurements made by the measurement device; repeating steps (a) to (d) in respect of a subsequent sub-set of data elements consecutive within the data set.

IPC Classes  ?

• G01S 7/48 - Details of systems according to groups , , of systems according to group
• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging

Abstract

Methods of treatment of complement-mediated disorders, in particular disorders associated with over-activity of the complement C3b feedback cycle (for example, age-related macular degeneration (AMI)), using gene therapy is described. According to the methods, levels of complement Factor I are elevated by administration of a recombinant viral vector encoding Factor I such that a therapeutically effective amount of the encoded Factor I is expressed from the vector in the subject. Recombinant viral vectors encoding Factor I, recombinant virus particles encapsidating the vectors, and their use in the methods of treatment, is also described.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C07K 14/75 - Fibrinogen
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to redox flow batteries (RFBs) which are tolerant to dioxygen, a method of preparing a RFB in the presence of dioxygen, and a method of charging and/or discharging a RFB and its use in the presence of dioxygen. The RFB comprises an electrolyte, the electrolyte comprising an organic redox-active molecule comprising a redox- active unit with two or more heteroarylene groups wherein the two or more heteroarylene groups are conjugated within the redox-active unit and at least a portion of the redox-active units are present as a complex formed of a singly reduced form of the redox-active unit, and wherein molecular dioxygen (O2) dissolved in the electrolyte. The RFB of the invention can be operated in the presence of dioxygen, removing the need for the creation of strict dioxygen-free conditions by purging, sealing and flowing inert gas through the RFB.

IPC Classes  ?

• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present disclosure provides a cell culturing apparatus (1) comprising an auxetic mesh (2) and a substrate (6) for culturing cells. The substrate (6) is attached to the auxetic mesh (2) such that a change in at least biaxial strain in the substrate (6) and/or the auxetic mesh (2) occurs by the application of a uniaxial force to the auxetic mesh (2). The present disclosure also provides a method of for culturing cells and a method of manufacturing a cell culturing apparatus.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

The present invention relates to an electrode comprising a reservoir containing a liquid, and an electrode material in contact with the reservoir and configured to absorb the liquid. The liquid in the reservoir is constituted such that the electrode maintains a low contact impedance with the skin of a subject over a long period of time. The invention also relates to a method of manufacturing an electrode, and a method of continuously hydrating an electrode.

IPC Classes  ?

• A61B 5/268 - Bioelectric electrodes therefor characterised by the electrode materials containing conductive polymers, e.g. PEDOT:PSS polymers
• A61B 5/265 - Bioelectric electrodes therefor characterised by the electrode materials containing silver or silver chloride
• A61B 5/259 - Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes using conductive adhesive means, e.g. gels

Abstract

Aspects of the present disclosure relate to methods of cultivating genetically altered plants with increased activity of one or more of a NODULATION SIGNALING PATHWAY 1 (NSP1) protein or a NODULATION SIGNALING PATHWAY 2 (NSP2) protein that have increased mycorrhization and/or promoted symbiotic responses under high phosphate and/or high nitrate conditions. Further aspects of the present disclosure relate to methods of cultivating genetically altered plants with increased activity of a C-TERMINALLY ENCODED PEPTIDE (CEP peptide) that have increased mycorrhization and/or promoted symbiotic responses under high phosphate and/or high nitrate conditions. In addition, aspects of the present disclosure relate to methods of cultivating these plants that include exogenous application of strigolactones, karrikins, and/or CEP peptides to increase mycorrhization and/or promote symbiotic responses under specific nutrient conditions.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof

Abstract

A medical device, comprising a flexible electrode array having a bend radius of no more than about 2mm; and a culture of biological cells on the flexible electrode array and integrated with the electrodes of the flexible electrode array.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof

Abstract

System and methods for identifying agents (e.g., proteins, peptides) that modulate G-protein coupled receptors (GPCRs) are generally described. For some embodiments, the agent is a nanobody that modulates the GPCR and may either act as an agonist (e.g., activate) or antagonist (e.g., deactivate) to the GPCR.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• C07K 19/00 - Hybrid peptides
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

System and methods for identifying agents (e.g., proteins, peptides) that modulate G-protein coupled receptors (GPCRs) are generally described. For some embodiments, the agent is a nanobody that modulates the GPCR and may either act as an agonist (e.g., activate) or antagonist (e.g., deactivate) to the GPCR.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

33) and has a thickness in the range 0.5 nm to 1 μm. The active layer is anisotropically strained in relation to an equilibrium phase for the composition so as to stabilise an active layer ferroelectric phase at a temperature of 20°C. The active layer may be epitaxial with respect to the substrate but with a lattice mismatch to provide said strain in the active layer to stabilise the active layer ferroelectric phase.

IPC Classes  ?

• C30B 25/02 - Epitaxial-layer growth
• C30B 25/10 - Heating of the reaction chamber or the substrate
• C30B 29/16 - Oxides
• H01L 21/00 - Processes or apparatus specially adapted for the manufacture or treatment of semiconductor or solid-state devices, or of parts thereof
• C30B 25/18 - Epitaxial-layer growth characterised by the substrate

Abstract

A method for computation on distributions of data, the method comprising providing a microarchitecture comprising: a first register containing data items; a second register containing distribution data representing distributions that are uncertainty representations associated with respective said data items; a first arithmetic logic unit for executing arithmetic on data items selected from the first register; a second arithmetic logic unit for executing arithmetic on distribution data selected from the second register; the method comprising the following steps implemented by the microarchitecture: executing, by the first arithmetic logic unit, an arithmetic operation on data items selected from the first register, and outputting the result; executing, by the second arithmetic logic unit, an arithmetic operation on distribution data representing distributions selected from the second register that are associated with the data items selected from the first register, and outputting the result; wherein the arithmetic operation executed on the distribution data selected from the second register is the same as the arithmetic operation executed on the data items selected from the first register thereby to generate further distribution data representing uncertainty associated with result of the arithmetic operation executed on the data items selected from the first register.

IPC Classes  ?

• G06F 9/30 - Arrangements for executing machine instructions, e.g. instruction decode

Abstract

Systems and methods for synthesising a controller of a robotic manipulator system are described, whereby a model of the robotic manipulator system is provided, the model including a plurality of control parameters associated with one or more virtual control mechanisms attached to respective locations of the robotic manipulator system, wherein output control actions of the model are defined based on said plurality of control parameters of the one or more virtual control mechanisms. Linear matrix inequality, LMI, constraints are determined for synthesis of control parameters that achieve a defined performance, wherein the LMI constraints define a gain matrix, K, consisting a plurality of diagonal matrices that correspond to the plurality of control parameters. A solution to the LMI constraints is derived, wherein the solution identifies control parameter values in the plurality of diagonal matrices. Output control actions are determined for one or more actuators of the robotic manipulator system based on the identified control parameter values.

IPC Classes  ?

• B25J 9/16 - Programme controls

Abstract

Broadly speaking, embodiments of the present techniques provide methods and systems for robot navigation in an unknown environment. In particular, the present techniques provide a navigation system comprising a navigating device and a sensor network comprising a plurality of static sensors. The sensor network is trained to predict a direction to a target object, and the navigating device is trained to reach the target object as efficiently as possible using information obtained from the sensor network.

IPC Classes  ?

• G05D 1/644 - Optimisation of travel parameters, e.g. of energy consumption, journey time or distance
• G05D 1/646 - Following a predefined trajectory, e.g. a line marked on the floor or a flight path
• G05D 101/15 - Details of software or hardware architectures used for the control of position using artificial intelligence [AI] techniques using machine learning, e.g. neural networks
• G05D 111/10 - Optical signals
• G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

This invention relates to antibodies that bind to and inhibit the activity of glial cell-derived neurotrophic factor family receptor alpha like (GFRAL) protein. The invention also relates to the GDF15-GFRAL signalling pathway as a therapeutic target for states of cachexia and conditions involving reduction in food intake and reduction in muscle and fat mass.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

A microscopic imaging method comprising: illuminating a three-dimensional object with a light sheet generated by an illumination optical system and capturing light-field information of the illuminated object with an imaging optical system.

IPC Classes  ?

• G01N 15/1434 - Optical arrangements
• G01N 15/149 - Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
• G02B 21/00 - Microscopes

Abstract

The invention relates generally to materials and methods of inhibiting Long Terminal Repeat Transposable Elements (LTR-TEs) during propagation of a plant by use of a reverse transcriptase inhibitor. Methods include propagation by plant tissue culture, comprising culturing an initial plant tissue in a culture medium comprising a reverse transcriptase inhibitor to obtain the cultured plant tissue, whereby inhibiting LTR-TEs leads to reduction in somaclonal variation in cultured plant tissue. Also provided are related media adapted for such culture, and plants and tissues which have reduced genetic variation as a result of the method.

IPC Classes  ?

• A01H 4/00 - Plant reproduction by tissue culture techniques

Abstract

The invention relates to methods and materials for use in treating neurodegenerative diseases associated with pathological protein aggregates and provides fusion proteins comprising: (i) a first portion comprising a sequence of a protein which aggregates pathologically in neurodegenerative disease, such as tau protein, and (ii) a second portion comprising a RING-type E3 ubiquitin ligase, a component of a RING-type E3 ubiquitin ligase complex, or a domain of either. These fusion proteins have utility in selectively or preferentially targeting pathogenic protein aggregates for degradation.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/82 - Translation products from oncogenes
• C12N 9/10 - Transferases (2.)

Abstract

This disclosure relates to a method of somatic cell nuclear reprogramming to alter the cell type comprising preparing a GV extract, permeabilising somatic cells, incubating the somatic cells with the GV extract to alter the cell type, and resealing somatic cell membranes, wherein said GV extract does not comprise oocyte cytoplasm. The disclosure also relates to a GV extract comprising reprogramming factors.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/075 - OocytesOogonia
• C12N 5/074 - Adult stem cells

Abstract

This invention relates to an RNA trans-splicing molecule (RTM) that targets human endogenous retrovirus (HERV) pre-mRNA. The RTM comprises (i) a binding region specific for a HERV pre-mRNA, (ii) a trans-splicing splice domain and (ill) a coding sequence for a suicide protein. The binding region of the RTM binds to HERV pre-mRNA in a cell, such that the coding sequence is trans-spliced through the trans- splicing domain with the HERV pre-mRNA, resulting in a chimeric mRNA causing the suicide protein to be expressed in the cell. RTMs of the invention may be useful in selectively killing cells that express HERV genes, for example cancer cells. RTMs, encoding nucleic acids, methods of treatment and associated methods and uses are provided.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

Methods for detecting diffusing particles are provided which comprise introducing a sample comprising a diffusing particle to an optical microcavity; coupling probe light into the optical microcavity such that the probe light is in resonance with the optical microcavity, wherein the diffusing particle diffuses into an optical mode volume defined by the coupled probe light; and detecting output light from the optical microcavity as a function of time while maintaining resonance, wherein the diffusing particle generates a change the detected output light. Systems for carrying out the methods are also provided.

IPC Classes  ?

• G01N 15/02 - Investigating particle size or size distribution
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited

Abstract

The present invention relates to a drug delivery device, a method to transport a charged species, a method to manufacture a drug delivery device, and a method to generate a charged fluid. A drug delivery device is configured to deliver a drug to a drug delivery site in a bodily tissue, the drug delivery device comprising a cavity configured to continuously receive a charged fluid, wherein the drug delivery device is configured to receive a charged particle comprising a drug in a space adjacent to the cavity and drive the charged particle from the space to the drug delivery site, the charged particle being driven by the action of an electric field generated by the charged fluid in the cavity.

IPC Classes  ?

• A61N 1/04 - Electrodes
• A61N 1/30 - Apparatus for iontophoresis or cataphoresis

Abstract

The invention relates to therapeutic uses of SARM1 agents (e.g. molecule that causes neurodegeneration and/or neuronal dysfunction in a SARM1 -dependent manner) such as Vacor, metabolites, analogs, and derivatives thereof for treating and/or preventing various diseases including neurological, ophthalmological, dermatological, gastroenterological, colorectal, urological, gynaecological, rheumatological, orthopaedic, dental, and/or ear nose and throat disease. Also provided are non-therapeutic uses of SARM1 agents metabolites, analogs and derivatives thereof, for example in methods for reducing or preventing skin changes such as wrinkles, contouring, and improving oily skin.

IPC Classes  ?

• A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system